Theialife has appointed ophthalmology industry veteran Thomas Ruggia as President and Chief Executive Officer, as the company prepares to advance its lead oral therapy for pediatric myopia into phase 3 development.
Ruggia brings more than 25 years of experience across ophthalmology, pharmaceuticals, and medical devices, with previous leadership roles at Johnson & Johnson, Alcon, and Novartis. He joins from Samsara Vision, where he served as CEO and led the global commercialization of an implantable miniature telescope for late-stage macular degeneration.
The leadership change comes at a pivotal moment for the late-stage clinical company, which is preparing to initiate phase 3 trials of ND10 (7-methylxanthine), a first-in-class oral therapy aimed at slowing myopia progression in children. The candidate is designed to modulate adenosine A2A receptors, enhancing dopamine activity and strengthening scleral collagen to reduce axial elongation.
According to the company, ND10 is supported by more than two decades of real-world and clinical data from Denmark, where over 1,200 children have been treated under compassionate use programmes, with encouraging efficacy and safety signals reported to date.
Co-founder Sundeep Aurora, who will remain chairman and continue to oversee R&D, described the appointment as aligned with the company’s transition into late-stage development and potential commercialisation.
“We believe that Tom’s deep expertise in ophthalmology makes him ideally suited to lead the next phase of our corporate and clinical evolution,” said Aurora. “With ND10, we have a first-in-class oral therapy with the potential to address one of the largest unmet needs in ophthalmology, and we are thrilled to have Tom join us to lead its continued advancement.”
Ruggia himself highlighted the growing global burden of pediatric myopia and positioned ND10 as a potential new therapeutic approach in a space currently dominated by optical and topical interventions, saying: “Theialife’s rigorous science and innovative ophthalmology platform has the potential to deliver desperately needed solutions for patients and transform the standard of care for a number of ocular diseases,”
Beyond myopia, Theialife is developing a broader ophthalmology pipeline, including programs in dry eye disease, wet AMD, and corneal blindness.
With phase 3 planning underway, the company is positioning itself for its next stage of clinical and corporate growth in an increasingly competitive ophthalmic therapeutics landscape.
Source: Theialife.
